Source: Zacks

Codiak: Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Read full article »
Codiak's Competitors | Codiak's News | Codiak's Financials
Stay up-to-date with the latest news on Codiak
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Douglas E. Williams's photo - President & CEO of Codiak

President & CEO

Douglas E. Williams

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Codiak